Heilongjiang, China

Lijia Jing

This inventor holds 1 USPTO granted patent. Top assignee: Northeast Forestry University. Active years: 2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lijia Jing. Retrieved from https://idiyas.com/inventor/lijia-jing

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lijia Jing: Innovator in Anti-Tumor Drug Development

Introduction

Lijia Jing is a notable inventor based in Heilongjiang, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-tumor drugs. His innovative work has led to the creation of a unique compound that holds promise for cancer treatment.

Latest Patents

Lijia Jing holds a patent for a derivative, preparation method, and use of 10-methoxycamptothecin. This patent describes a 10-methoxycamptothecine derivative of a specific formula, where R can be selected from various chemical groups, including hydrogen, Calkyl, Chaloalkyl, and others. The invention also details the preparation method of the derivative and its application in anti-tumor drug preparation.

Career Highlights

Lijia Jing is affiliated with Northeast Forestry University, where he continues to engage in research and development. His work focuses on innovative solutions in the pharmaceutical industry, particularly in creating effective treatments for cancer.

Collaborations

Lijia Jing collaborates with Xiufeng Yan, a fellow researcher who contributes to his projects. Their partnership enhances the research efforts in developing new pharmaceutical compounds.

Conclusion

Lijia Jing's contributions to anti-tumor drug development through his innovative patent demonstrate his commitment to advancing medical science. His work is a testament to the importance of research in finding effective treatments for cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…